Zhou Yong at the Department of Orthopedics of West China Hospital of Sichuan University: There are no drugs for patients with tendon sheath giant cell tumors that cannot be surgery in China

Cover reporter Wu Yujia

"Persverse tendon sheath giant cell tumors are destructive to normal tissue, wide range of destruction, and often difficult to remove clean surgery. The recurrence rate is very high, which seriously affects the physical function and quality of life of patients." Recently, the drugs of the China National Drug Administration The review center (CDE) is determined to be a breakthrough treatment drug for treatment of non -surgically removed tendon sheath giant cell tumor ABSK021 in the process of clinical trial. For patients with tendon sheath giant cell tumors who cannot be completely removed and obtained by good treatment effect, it is of great significance. "

It is understood that the tendon sheath giant cytoma is divided into limitations and diffuseness, and the incidence rate is about 43 %, of which about one -tenth of the permeability is a rare disease. Although tendon sheath giant cytoma is a benign tumor, but because of the early symptoms, patients have a late medical treatment, and often have a wide range of tumors during medical treatment, and it is difficult to remove thoroughly. And the tumor is not effective for chemotherapy, so the recurrence rate and residual rate are very high.

"At present, surgery has reached the bottleneck." Associate Professor Zhou Yong introduced. "First, tumors often invade the important blood vessel nerves of parcels of parcels and extensively infringe on normal tissue. There may be limb ischemic necrosis or nerve injury after the loss of the limb function; second, tumors often violate the arthone synovium, joint cavity, cartilage, skeletal, muscles, tendon, and wrap vascular nerves, even if more in installments, The secondary surgical resection, the recurrence rate is still very high. Repeated recurrence not only causes the patient's limb pain and severe dysfunction, but even the normal structure is damaged, and eventually amputation. This disease is mostly in the middle age of youth. During the golden time of the right track, the disease has a huge impact on the physiological and psychological of the patient, and the treatment needs of patients are very high, so it is urgent to innovate therapy. "

Studies have shown that excessive expression of CSF1 is the main cause of tendon sheath giant cytoma, blocking the CSF1/CSF-1R pathway provides a new choice for the systemic therapy TGCT. At present, He Yu Pharmaceutical ABSK021 is used to treat tendon sheath giant cell tumors in the United States. The clinical phase 1A dose climbing test is currently being launched in China and the United States.

Associate Professor Zhou Yong for example, "There is a patient with a long recurrence of the knee joints tendon sheath giant cell tumor, which can no longer be walked when entering the group. After two courses of treatment after clinical trials, the tumor has been significantly reduced. The patient has already been Walking freely. Another patient with a huge hip joint of a tendon sheath giant cell tumor, the affected limb before entering the group is significantly thicker than the opposite side. After a cycle of medication, the patient's tumor is significantly reduced. The effect is very obvious. Therefore, according to the good therapeutic effects and safety displayed by the current clinical trials, we very much hope that this medicine can benefit the majority of patients as soon as possible. "

- END -